BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 21205913)

  • 1. BeKm-1, a peptide inhibitor of human ether-a-go-go-related gene potassium currents, prolongs QTc intervals in isolated rabbit heart.
    Qu Y; Fang M; Gao B; Chui RW; Vargas HM
    J Pharmacol Exp Ther; 2011 Apr; 337(1):2-8. PubMed ID: 21205913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of autoimmune response to the extracellular loop of the HERG channel pore induces QTc prolongation in guinea-pigs.
    Fabris F; Yue Y; Qu Y; Chahine M; Sobie E; Lee P; Wieczorek R; Jiang XC; Capecchi PL; Laghi-Pasini F; Lazzerini PE; Boutjdir M
    J Physiol; 2016 Nov; 594(21):6175-6187. PubMed ID: 27296897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
    Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
    Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro.
    Fanoe S; Jensen GB; Sjøgren P; Korsgaard MP; Grunnet M
    Br J Clin Pharmacol; 2009 Feb; 67(2):172-9. PubMed ID: 19159406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for a crucial modulating role of the sodium channel in the QTc prolongation related to antipsychotics.
    Silvestre JS; O'Neill MF; Prous JR
    J Psychopharmacol; 2014 Apr; 28(4):329-40. PubMed ID: 24327451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BeKm-1 is a HERG-specific toxin that shares the structure with ChTx but the mechanism of action with ErgTx1.
    Zhang M; Korolkova YV; Liu J; Jiang M; Grishin EV; Tseng GN
    Biophys J; 2003 May; 84(5):3022-36. PubMed ID: 12719233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A radiolabeled peptide ligand of the hERG channel, [125I]-BeKm-1.
    Angelo K; Korolkova YV; Grunnet M; Grishin EV; Pluzhnikov KA; Klaerke DA; Knaus HG; Møller M; Olesen SP
    Pflugers Arch; 2003 Oct; 447(1):55-63. PubMed ID: 12905030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SKF-96365 blocks human ether-à-go-go-related gene potassium channels stably expressed in HEK 293 cells.
    Liu H; Yang L; Chen KH; Sun HY; Jin MW; Xiao GS; Wang Y; Li GR
    Pharmacol Res; 2016 Feb; 104():61-9. PubMed ID: 26689773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional Impact of BeKm-1, a High-Affinity hERG Blocker, on Cardiomyocytes Derived from Human-Induced Pluripotent Stem Cells.
    De Waard S; Montnach J; Ribeiro B; Nicolas S; Forest V; Charpentier F; Mangoni ME; Gaborit N; Ronjat M; Loussouarn G; Lemarchand P; De Waard M
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel.
    Kang J; Chen XL; Wang H; Ji J; Cheng H; Incardona J; Reynolds W; Viviani F; Tabart M; Rampe D
    Mol Pharmacol; 2005 Mar; 67(3):827-36. PubMed ID: 15548764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?
    Lu HR; Hermans AN; Gallacher DJ
    Br J Pharmacol; 2012 Jun; 166(4):1490-502. PubMed ID: 22300168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys.
    Watson KJ; Gorczyca WP; Umland J; Zhang Y; Chen X; Sun SZ; Fermini B; Holbrook M; Van Der Graaf PH
    J Pharmacol Toxicol Methods; 2011; 63(3):304-13. PubMed ID: 21419854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction simulation of hERG K+ channel with its specific BeKm-1 peptide: insights into the selectivity of molecular recognition.
    Yi H; Cao Z; Yin S; Dai C; Wu Y; Li W
    J Proteome Res; 2007 Feb; 6(2):611-20. PubMed ID: 17269718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of probucol, a typical hERG expression inhibitor, on in vivo QT interval prolongation in conscious dogs.
    Nogawa H; Kawai T; Yajima M; Miura M; Ogawa T; Murakami K
    Eur J Pharmacol; 2013 Nov; 720(1-3):29-37. PubMed ID: 24211675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human embryonic stem cell derived cardiac myocytes detect hERG-mediated repolarization effects, but not Nav1.5 induced depolarization delay.
    Qu Y; Gao B; Fang M; Vargas HM
    J Pharmacol Toxicol Methods; 2013; 68(1):74-81. PubMed ID: 23518063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated perfused and paced guinea pig heart to test for drug-induced changes of the QT interval.
    Cheng HC; Incardona J; McCullough B
    J Pharmacol Toxicol Methods; 2006; 54(3):278-87. PubMed ID: 16507347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis of the Novel Autoimmune-Associated Long-QT Syndrome.
    Yue Y; Castrichini M; Srivastava U; Fabris F; Shah K; Li Z; Qu Y; El-Sherif N; Zhou Z; January C; Hussain MM; Jiang XC; Sobie EA; Wahren-Herlenius M; Chahine M; Capecchi PL; Laghi-Pasini F; Lazzerini PE; Boutjdir M
    Circulation; 2015 Jul; 132(4):230-40. PubMed ID: 25995318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolongation of cardiac ventricular repolarization under paliperidone: how and how much?
    Vigneault P; Kaddar N; Bourgault S; Caillier B; Pilote S; Patoine D; Simard C; Drolet B
    J Cardiovasc Pharmacol; 2011 Jun; 57(6):690-5. PubMed ID: 21394035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
    Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
    J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QT interval prolongation and cardiac risk assessment for novel drugs.
    Picard S; Lacroix P
    Curr Opin Investig Drugs; 2003 Mar; 4(3):303-8. PubMed ID: 12735231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.